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Abstract 
Background 
Shared decision making contributes to high quality healthcare by promoting a patient-
centered approach. Patient involvement in selecting the components of a diabetes medication 
program that best match the patient’s values and preferences may also enhance medication 
adherence and improve outcomes. Decision aids are tools designed to involve patients in 
shared decision making, but their adoption in practice has been limited. In this study, we 
propose to obtain a preliminary estimate of the impact of patient decision aids vs. usual care 
on measures of patient involvement in decision making, diabetes care processes, medication 
adherence, glycemic and cardiovascular risk factor control, and resource utilization. In 
addition, we propose to identify, describe, and explain factors that promote or inhibit the 
routine embedding of decision aids in practice. 
Methods/Design 
We will be conducting a mixed-methods study comprised of a cluster-randomized, practical, 
multicentered trial enrolling clinicians and their patients (n = 240) with type 2 diabetes from 
rural and suburban primary care practices (n = 8), with an embedded qualitative study to 
examine factors that influence the incorporation of decision aids into routine practice. The 
intervention will consist of the use of a decision aid (Statin Choice and Aspirin Choice, or 
Diabetes Medication Choice) during the clinical encounter. The qualitative study will include 
analysis of video recordings of clinical encounters and in-depth, semi-structured interviews 
with participating patients, clinicians, and clinic support staff, in both trial arms. 
Discussion 
Upon completion of this trial, we will have new knowledge about the effectiveness of 
diabetes decision aids in these practices. We will also better understand the factors that 
promote or inhibit the successful implementation and normalization of medication choice 
decision aids in the care of chronic patients in primary care practices. 
Trial registration 
NCT00388050 
Keywords 
Diabetes, Shared decision making, Cardiovascular prevention, Implementation 
Background 
Type 2 diabetes mellitus is a metabolic derangement of epidemic impact that lowers the 
quality and duration of life for millions [1]. The public health impact of this epidemic is best 
understood when considering that diabetes is associated with an increased risk of premature 
death (mostly from cardiovascular causes), cardiovascular disease, blindness, renal failure, 
chronic neuropathic pain, and limb amputations. Successful management of type 2 diabetes 
requires preventive care and incorporation of healthy nutritional and activity habits. 
Pharmacologic therapy to achieve metabolic control and favorably impact risk factors 
associated with diabetes-related complications is almost always necessary. Several 
medications to control hyperglycemia, hypertension, and dyslipidemia have become available 
in the last decades. Patients who experience the use of these medicines, often in combination, 
and their costs and side effects often report their burden to exceed the perceived burden of 
diabetes complications [2,3]. 
A patient-centered approach to care that promotes patient involvement in selecting the 
intensity and components of a complex diabetes medication program to better match patient 
values and preferences contributes to high quality care and may enhance medication 
adherence [4]. Decision aids, tools to help involve patients in decision making by clearly and 
accessibly presenting the available options and their relative advantages and disadvantages, 
may facilitate patient-centered care [5]. In close collaboration with a multidisciplinary team 
of patients, clinicians, and designers, we have developed decision aids targeting glycemic and 
cardiovascular risk factor control through medication therapy (Diabetes Medication Choice, 
Statin Choice) [6,7]. These tools have been shown to improve patient knowledge, 
involvement in the decision making process, and satisfaction with healthcare [6,8]. In 
addition, ninety percent of the clinicians considered the decision aids helpful and would use 
these decision aids in their practice [8]. 
Despite their efficacy [5], the adoption of decision aids in practice has been dismal for 
reasons that remain unclear. Furthermore, limited evidence supports our understanding of 
how decision aids become routinely implemented, embedded, and sustained in practice—that 
is, how they become normalized. Current approaches to understanding the implementation of 
decision aids in practice have included analyses of the barriers to using decision aids [9], and 
problems of individual behavioral change [10] or organizational diffusion. To our knowledge, 
there is no practice-based research focused on how to normalize these decision aids in the 
routine of busy clinical practices and on evaluating the effectiveness of diabetes decision aids 
on patient, clinician, and practice outcomes. Thus, there is urgent need to conduct patient-
centered translational practice-based research in diabetes care. 
To pursue this effort we propose to 1) evaluate, in a cluster-randomized practical trial 
enrolling primary care practices and their patients with type 2 diabetes, the impact of patient 
decision aids vs. usual care on measures of patient involvement in decision making, diabetes 
care processes, medication adherence, glycemic and cardiovascular risk factor control, and 
resource utilization; and 2) identify, describe, and explain, using a theory-driven qualitative 
research approach, factors that promote or inhibit the routine embedding of decision aids in 
the rural and suburban practices participating in the randomized trial. 
Methods 
Study design 
We will be conducting a mixed-methods study comprised of a cluster-randomized, practical, 
multi-centered trial enrolling primary care practices with a qualitative study embedded to 
examine how the practices will be incorporating the decision aids into their clinical routines 
(Figure 1). The Mayo Clinic and Olmsted Medical Center Institutional Review Boards (IRB) 
have approved the study procedures described herein. 
Figure 1 Study design 
Setting 
We will recruit clinicians and their patients with type 2 diabetes receiving routine diabetes 
care from participating primary care practices of Olmsted Medical Center across rural and 
suburban communities in Southeastern Minnesota, USA. 
Study participants and eligibility criteria 
Clinical practices. Eligible practices are those that have prioritized chronic disease care as an 
area for quality improvement and have served at least 50 patients with type 2 diabetes in the 
12 months prior to the eligibility assessment. Primary care clinicians. We will recruit 
clinicians, defined as professionals with patient healthcare responsibilities (i.e., physicians, 
nurse practitioners, physician assistants), from participating practices if they are providing 
care to adults with type 2 diabetes. Patients. We will consider eligible adult patients (≥18 
years) with type 2 diabetes if they recognize the participating clinician as their main diabetes 
care provider, have no major barriers to provide written informed consent (e.g., severe 
hearing impairment, dementia), can communicate in English, and declare being available for 
a six-month follow-up. Furthermore, these patients should need to start, intensify, or modify 
their antihyperglycemic treatment. Additional criteria will be used to identify eligibility 
according to designated study arms (Figure 2). 
Figure 2 Eligibility criteria and assignment by arms 
Participant recruitment 
We will send an introductory letter providing an overview of the study and inquiring about 
potential interest to eligible practices. Study team members will then personally visit 
interested clinics to discuss the study in more detail with clinic leaders. We will identify a 
lead clinician (“clinical champion”) to become the contact person for each practice for the 
duration of the study and seek participation of clinicians during this first meeting when the 
study is discussed. Potentially eligible patients will be identified through the diabetes registry, 
and we will note their upcoming appointments with participating clinicians. A study team 
member will contact these patients in advance to seek their participation in the study. Trained 
study personnel will obtain written informed consent to participate in the study from both 
clinicians and patients prior to their clinical encounter. 
Allocation procedures 
Randomization will be by practice. The study will compare the use of the decision aids within 
the clinical encounter versus usual care. We will identify pairs of practices that are most 
similar in size (i.e., number of clinicians seeing adult patients with type 2 diabetes) and 
randomize within each pair to use either the 1) the Statin Choice and the Aspirin Choice, or 2) 
the Diabetes Medication Choice decision aid. Each practice will also serve as the usual care 
arm for the other intervention arm (Figure 2). This approach will seek to ensure similar 
representation of ‘easy’ and ‘difficult’ practices in both decision aid groups and eliminate the 
need for any site to simply serve as a usual care arm. A study statistician will perform the 
randomization centrally after the practices have been enrolled, ensuring concealment of 
allocation of the paired practices. Practices, clinicians, patients, and investigators will not be 
masked to the intervention. However, patients providing outcomes will remain masked to 
their practice status, as consent documents will keep patients unaware of the study’s main 
hypotheses. Furthermore, we will centrally follow patients and ensure that patient surveys 
and pharmacy follow-up are completed according to the intention-to-treat principle. 
Intervention 
The intervention will consist of the use of a decision aid (Statin Choice and Aspirin Choice, 
or Diabetes Medication Choice) by patients and their primary care clinician during the 
clinical encounter (http://kercards.e-bm.info). 
Decision aids 
The Statin Choice decision aid has three different versions according to baseline 10-year 
cardiovascular risk, pre-assessed for each patient: 10% (used for patients with a 10-year 
cardiovascular risk <15%), 20% (for patients with estimated risk between 15 and 30%), and 
50% (for patients with estimated risk >30%) [6,11]. The decision aid also presents the 
absolute risk reduction of cardiovascular events with statins, the potential downsides of 
taking statins, and a question prompting patients to express whether they are ready or not to 
make a decision and consequently which action they would like to take. The Aspirin Choice 
decision aid is similar to the Statin Choice decision aid with the only difference being that it 
presents the absolute risk reduction of cardiovascular events with aspirin. The Diabetes 
Medication Choice decision aid takes the form of cards that compare commonly used 
diabetes medication classes across several domains (e.g., reduction in HbA1c, weight gain, 
cost, mode of administration) that patients with type 2 diabetes and clinicians consider 
important when choosing these medications [7,8]. 
Training of clinicians 
A study team member will conduct a demonstration showing how to use the decision aid at 
the time of the initial in-person discussion with clinics. The focal points of the demonstration 
will be that decision aids serve as guides for conversation rather than scripted discussions; 
that clinicians have flexibility in the manner in which they use the decision aid, including 
how and when they use them during the visit; and that they may elect not to use the tools with 
certain enrolled patients, per their own judgment. Brief video clips and storyboards that 
demonstrate the basic use of decision aids are publicly available at http://kercards.e-bm.info 
for clinicians to review at their convenience. A study team member will remain available to 
do one-on-one demonstrations after the initial group demonstration if needed. 
Usual care 
For patients in the usual care arm, clinicians will manage the discussion about medication 
regimen as usual, without using decision aids. 
Frameworks 
The RE-AIM framework will guide this study (aim 1). This framework has been developed 
specifically to address how an intervention, in this case use of decision aids, is implemented 
in a real-world setting [12,13]. Dimensions of the RE-AIM include: Reach (how broadly is 
this intervention used within the practices), Effectiveness (what is the impact of the 
intervention on outcomes), Adoption (can this be adopted by new groups with ease and 
minimal modifications), Implementation (what are the special issues and barriers in 
implementation), and Maintenance (can the intervention be maintained and will the impact 
continue) [12,13]. To complement the RE-AIM framework, we will use the Normalization 
Process Theory (aim 2) [6,14]. This applied theoretical model focuses attention on the 
practical work that facilitates understanding of the factors that promote and inhibit the routine 
embedding of interventions, such as decision aids into practice, in a structured and 
parsimonious way. The combination of an established implementation framework and robust 
explanatory model will provide a strong foundation for process evaluation of the trial. 
Data collection & analysis 
Aim 1. Evaluating the impact of patient decision aids 
We will collect patients’ data through 1) self-reported questionnaires administered before and 
after the clinical encounter with their clinician, and at 3 and 6 months post encounter; and 2) 
information about diabetes-related care included in medical records. Participating clinicians 
will be given a brief questionnaire to complete immediately following each clinical encounter 
with a participating patient. In addition, we will videotape each clinical encounter. Practice 
data will be obtained from administrative and patient medical records. 
Outcomes measures 
To assess Effectiveness of the decision aids (RE-AIM) we will measure the decisional 
conflict as the primary outcome and patient involvement in decision making, diabetes care 
processes, medication adherence, glycemic and cardiovascular risk factor control, and 
resource utilization as secondary outcomes, in the following way: 
• Patients’ decisional conflict. Patients will complete, immediately after the clinical 
encounter with their clinician, a modified version of the Decisional Conflict Scale [15], the 
most commonly used outcome measure in decision aid trials [5]. These modifications entail 
the use of brief items that explore the quality of the deliberation process during the visit. 
Psychometric properties include good internal consistency, test–retest reliability, and effect 
sizes for responsiveness to change ranging from 0.4 to 1.2 [15,16]. 
• Patients’ involvement in decision making. We will use the OPTION scale to assess the 
extent to which clinicians seek to engage patients in decision making [17,18]. OPTION is a 
third-person observer scale and was designed for use in reviewing audio recordings of 
primary care visits. Our group has extended the use of this tool to video recordings with 
excellent inter-rater reliability (intraclass correlation coefficient >0.7) [6,19,20]. 
• Patients’ knowledge. Patients will complete a knowledge questionnaire immediately 
following the encounter with their clinicians, and at 3 and 6 months post-encounter. The 
questionnaire was developed according to prior recommendations and is similar to 
questionnaires used in our previous studies, addressing general knowledge about diabetes and 
lipid management and specific information contained in the decision aids [6,8]. 
• Patients’ satisfaction. Satisfaction with decision making will be assessed using items from 
the Decisional Conflict Scale [15] as well as two specific questions that require patients to 
assess the extent to which they would want for themselves and recommend to others similar 
decision support as they received during the visit. Other questionnaires exist to specifically 
address this domain, but our use of the Decisional Conflict Scale for this purpose reflects our 
effort to minimize participant burden. 
• Patients’ quality of life. Patients will assess their health-related quality of life prior to the 
clinical encounter through the use of the EuroQol EQ-5D scale in which they list their health 
as excellent, very good, good, fair or poor [21]. The EQ-5D has been used in primary care 
[22,23] and in diabetes care and diabetes trials [24,25]. 
• Patients’ hemoglobin A1c, lipids, blood pressure, & body mass index. Medical records 
will be the source of information about these commonly used intermediate outcome measures 
for diabetes [26,27]. 
• Patients’ prescription drugs. Prescription drug and billing data will be collected through 
pharmacy records. Patients will be asked to provide written authorization to contact their 
pharmacy and release this information to the investigators. We have been able to obtain 
complete pharmacy records for all of our participants in previous trials [6,8]. 
• Patients’ adherence. Adherence and persistence measures will be derived from patient 
self-report, metabolic outcomes (indirect measure), and pharmacy records. These diverse 
sources are necessary given the nature of medications (e.g., multiple dosing and dose 
adjustments, particularly of insulin, for diabetes medication) [28,29]. 
• Clinicians’ satisfaction. Clinicians will complete a brief questionnaire after each 
encounter where we will ask about their satisfaction regarding the discussion they had with 
their patient about starting a medication. 
• Costs and resource utilization. We will collect cost and utilization data from patients 
using two methods: first, by attempting to collect billing data from all clinicians the patient 
reports seeing in the six-month period and second, by collecting data on resource utilization 
from the patient questionnaire at six months. Data collected will include the number of 
hospitalizations, reason for hospitalization, whether the hospitalization was for medical or 
surgical condition, and the length of hospital stay. Additionally, we will collect data on 
emergency room and ambulatory care utilization. This utilization data will be costed 
according to the methods described by Glick et al. [30]. We will evaluate the economic 
impact of decision aid implementation from the clinician perspective based on the length of 
visits. The incremental time for decision aid visits will be considered the opportunity cost of 
using a decision aid. We will convert this incremental time to potential number of additional 
diabetes-related visits that could have been scheduled in 12-months in place of decision aid 
assisted visits. The visits will be costed using the Medicare Fee schedule for a diabetes-
related visit. We will add the costs of materials (decision aids) to estimate the total practice-
related costs. 
To assess the Reach of the decision aids (RE-AIM), we will use a tracking log to record 
patients who are enrolled as well as those who declined the invitation to participate. We will 
use this data to evaluate reach, e.g., the ratio of enrolled patients to invited patients in each 
clinic and the characteristics of eligible patients who enrolled and declined. This will allow us 
to measure participation and representativeness. 
To assess the Adoption of the decision aids (RE-AIM), we will estimate the proportion of 
practices or clinicians who adopt the intervention. Using clinician surveys and medical record 
review, we will compare the adoption rates across the intervention practices. We will select a 
random sample of medical records from each site to determine the extent to which the use of 
the decision aid is discernible in the records, and the extent of use and success when 
mentioned. 
To assess the Implementation of the decision aids (RE-AIM), we will seek to determine the 
extent to which the intervention is implemented as intended. Using the video recordings of 
the clinical encounters, we will assess the fidelity with which the decision aids are delivered 
and used as intended during these clinical encounters. We have developed a fidelity checklist 
for each of the decision aids. These checklists have 10 to 12 items and are completed by a 
third observer reviewing the video recordings of the encounters [20]. 
To assess the Maintenance of the decision aids (RE-AIM), we will conduct a site visit and 
medical record review of eligible patients, approximately six months after removing 
investigator implementation support from the sites. This medical record review is in addition 
to the reviews that will take place at three and six months following the study visit. 
Socio-demographic characteristics 
We will ask patients to report demographic information that is not available in the medical 
record, such as marital status, years of education, occupation, and household income. We will 
collect the following characteristics for clinicians: type of practice, years in practice and at 
practice site, gender, birth year, ethnicity, race, estimate of time in direct patient care, 
proportion of practice devoted to patients with diabetes, and average length of appointments 
with diabetes patients. Data will be collected to characterize participating practices including 
race, ethnicity, and insurance status of patients seen in the practice; practice type, community 
size, and make-up of staff including clinicians, allied health staff, and patient educators. 
Sample size 
A total of 8 practices will be randomized to 1) the Diabetes Medication Choice decision aid 
plus statin and aspirin usual care or 2) the Statin Choice and Aspirin Choice decision aids 
plus diabetes medication usual care. The Statin Choice cluster randomized trial evaluated 
decision quality comparing the decision aid to usual care. This study reported a 9.8 point 
difference in decision quality3 with the standard deviation of 16.9 and 14.1 for the usual care 
and decision aid groups, respectively. Making the following assumptions: 1) variances are as 
reported in this study; 2) we seek to detect a difference of 9.8 points or greater in decision 
quality between two groups at significance level of 0.05, with a two-sided t-test; 3) a modest 
correlation of outcomes across these clinicians and practices (which is a conservative 
assumption) represented by an intracluster correlation coefficient (ICC = between cluster 
variance/total variance) of 0.05; 4) a variance inflation or design effect factor [1+ (n − 1) · 
ICC], where n is the number of patients per cluster [31]; and 5) an approximated 20% 
attrition rate, we will have 80% power if we are able to recruit 30 patients per clinic for a 
total recruitment target of 240 patients. Assuming a similar ICC and attrition rate for other 
outcomes, this sample size will have 99% power to detect a 1 SD difference in any 
continuous measure (e.g., approximately a 2-point difference in a 10-question knowledge 
scale), and 80% power to detect a 30% difference in 6-month adherence rates assuming a 
control adherence rate of 50%. Actual power will be likely greater because we will adjust for 
baseline values and characteristics and because of our conservative assumptions. 
Analysis 
We will have a summary of the cluster level and patient level characteristics within each trial 
arm, providing counts and frequencies for categorical variables and means with ranges for 
continuous variables. Because of the uncertainty as to the ability of a cluster trial to create 
uniform prognostic groups, we will test the null hypothesis of no difference between arms in 
baseline cluster level characteristics using the weighted paired t-test [32]. This test can 
account for the small number of clusters and an unequal number of patients within each 
cluster. 
To account for the modified study design (e.g., each arm being both intervention and usual 
care), the study team assumes similar adherence rates within statin medications and diabetes 
medications along with similar knowledge, decisional conflict, and satisfaction rates for 
patients discussing either medication for those within the usual care group. For the decision 
aids (Statin, Aspirin and Diabetes Medication) the study team assumes the same impact on all 
of these outcomes for all decision aids. With these assumptions, all patients that use a 
decision aid during the encounter of interest will be grouped in the decision aid arm and those 
that do not will be grouped under the usual care arm. To account for differences that may 
exist between the diabetes, statin, and aspirin patients, all models will be adjusted by group. 
Interaction between arm and group will be tested for significance, recognizing that the study 
will be underpowered to test for this interaction. 
To evaluate the efficacy of the intervention, differences in all patient level outcomes, for both 
continuous and dichotomous outcomes (as well as patient characteristics at baseline) will be 
estimated using the random effects meta-analysis method [31]. This approach has been 
validated for matched pair cluster-based studies: differences in means for continuous 
outcomes and in proportions for dichotomous outcomes are estimated and then pooled across 
strata. A stratum in terms of a matched-pair study is considered to be each pair, and in this 
trial there are 5 strata. For each outcome, we will thus estimate the effect size and its 
precision (e.g., 95% confidence interval). The outcomes will be assessed at baseline, 3 and 6 
months. We will estimate the intraclass correlation coefficient for each outcome along with 
its 95% confidence interval and report these for informational purposes only since the 
number of clusters is insufficient to determine with confidence a true intraclass correlation124. 
Within patients that had a diabetes medication discussion, HbA1c will be collected and 
categorized to <7.3 versus ≥7.3. This outcome will be analyzed as described above for 
categorical outcomes. All analysis and data management will be conducted utilizing SAS 
(version 9, Cary, NC) with use of Stata statistical software (version 11.0, College Station, Tx) 
for primary endpoint analysis. 
Patients with missing outcome data will not be included in assessment of that particular 
outcome. We will compare the incidence of missing data for each outcome between study 
arms, both absolutely and as a function of follow-up period. We will report rates of missing 
data for each outcome by study arm and known reasons for missing data. In the event that the 
rate of missing data is not independent of study arm or is greater than the assumed 10% loss 
to follow-up, we will conduct sensitivity analyses under a range of assumptions about the 
missing values and assess consistency of results across those scenarios. In the event that 
patients are missing baseline characteristics data, which are otherwise imbalanced between 
the two study groups, we will use imputations to estimate models which include those 
characteristics. 
Aim 2. Identify, describe, and explain factors that promote or inhibit the routine 
embedding of decision aids in urban and nonurban practices 
To evaluate how the decision aids are routinized into primary care practice, we will conduct a 
qualitative study with a subset of participants (patients, clinicians, and clinic support staff) at 
the study sites. The qualitative study will have two major components, which will include 1) 
a qualitative analysis of video-recordings of clinicians/patients clinical encounters in both 
intervention and usual care arms, and 2) in-depth, semi-structured interviews with 
participating patients, clinicians, and clinic support staff, in both intervention and usual care 
arms. 
In addition to the video recordings of the clinical encounters, we will conduct semi-
structured, in-depth, interviews with participating patients, clinicians, and clinic support staff 
(Figure 1). Patients will be interviewed within a few weeks after their clinical encounter so as 
to remember the details of the visit. Clinicians will be interviewed after all patient 
recruitment has been completed so as to reflect on their management of several different 
patients during this study, both in intervention and usual care arms. Clinic support staff (e.g., 
receptionists, nurses, and medical assistants) will be interviewed based on their involvement 
with the study. An experienced qualitative researcher will lead these interviews and audio-
record them with participant consent. Interviews will be no longer than one hour and will be 
held at the participating site, at a time deemed most convenient for the participant. When 
appropriate, clinicians will review excerpts of their own video-recordings of clinical 
encounters. 
Sample size 
From the video recordings of clinical encounters from both arms, we will seek to identify a 
maximum variation sample of 30 encounters, according to patient age (<65 or ≥65), whether 
the patient is accompanied during the visit, and whether there is gender congruence between 
patient and clinician. We will conduct between 20 and 40 interviews for both, participating 
patients and clinicians, in the intervention and usual care arms of the trial. We will conduct 
between 10 and 20 interviews with clinic support staff, with a purposive sample that are most 
likely to be affected by the use of the decision aid. 
Analysis 
Patient and clinician interviews and video-recordings of clinical encounters will be fully 
transcribed, including observational notes of how the decision aids are used. A qualitative 
analysis team of at least 6 people will conduct data analysis by using standard qualitative 
content analysis techniques [33-35]. Trustworthiness of the analysis will be ensured by: 1) 
assessing transcripts for consistency, 2) group coding, 3) coding the first round individually, 
and 4) coding subsequent rounds reiteratively. The analysis team will identify key themes and 
will code interview and clinical encounter transcripts in an iterative process. The team will 
use qualitative data management software (NVivo 9.0) to facilitate data organization and 
coding. Each transcript will be independently coded by at least two team members to 
establish internal validity. Consensus will be reached through discussion. Codes, which have 
quotations assigned to them, will be examined by all analysis team members to ensure 
consistent code usage. Coded data will be compiled and analyzed in the form of memos as a 
data reduction strategy to build a conceptual model that resonates with the constructs of 
Normalization Process Theory `6,14]. An observational guide will be used to analyze the 
videotaped encounters. The guide is designed to document initiation of discussion, length of 
discussion, engagement of patient in discussion, topics discussed, use of context, and 
integration of decision aids into the medication choice discussion. 
Discussion 
The proposed trial seeks to determine the impact of patient decision aids vs. usual care on 
measures of patient involvement in decision making, diabetes care processes, medication 
adherence, glycemic and cardiovascular risk factor control, and resource utilization in urban 
and rural practices in the Midwestern United States. Upon completion of this trial, we will 
have new knowledge about the effectiveness of diabetes decision aids in these practices and 
about the processes that promote or inhibit the successful implementation and normalization 
of medication choice decision aids in rural and urban primary care practices. 
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